跳至主要内容
临床试验/RBR-10cr49dr
RBR-10cr49dr已完成未知

Analysis of foraminal patency attainment rates by undergraduate students - An in vivo Study

niversidade Paranaense0 个研究点开始时间: 2021年12月13日最近更新:

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
0 至 0(—)

入选标准

  • Patients with one or more dental elements indicated for radical endodontic treatment; complete rhizogenesis

排除标准

  • Dental elements with previously performed endodontic treatments; root curvatures; root resorption processes; anatomical complexities

研究者

发起方
niversidade Paranaense

相似试验

尚未招募
不适用
The relationship between the patency rate of infrapopliteal lesions after endovascular treatment and wound healing rate in critical limb ischemia with tissue losscritical limb ischemia
JPRN-UMIN000016098Saiseikai Yokohama-city Eastern Hospital50
进行中(未招募)
不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CR-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trial
EUCTR2005-005139-84-ATPIERRE FABRE MEDICAMENT200
进行中(未招募)
不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CT-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialocally advanced non small cell lung cancer
EUCTR2005-005139-84-CZPIERRE FABRE MEDICAMENT200
进行中(未招募)
1 期
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CT-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialocally advanced non small cell lung cancerMedDRA version: 8.1Level: LLTClassification code 10025044Term: Lung cancer
EUCTR2005-005139-84-FIPIERRE FABRE MEDICAMENT200
进行中(未招募)
1 期
Evaluation of the rate of pathological complete response for neoadjuvant chemoradiotherapy and for chemotherapy alone in locally advanced lung cancer.ocally advanced non small cell lung cancer
EUCTR2005-005139-84-ESPIERRE FABRE MEDICAMENT200